GEN Exclusives

More »

GEN News Highlights

More »
Oct 2, 2007

PerkinElmer Offers $300M for ViaCell to Augment Neonatal Genetic Screening Business

  • PerkinElmer plans to take over ViaCell for approximately $300 million. The acquisition of its umbilical cord blood preservation product, ViaCord, will complement PerkinElmer’s neonatal genetic screening program.

    The agreement calls for PerkinElmer to pay $7.25 per ViaCell share, a premium of almost 52%. ViaCell’s stock price spiked, opening the day at $7.15, the highest it’s traded since 2005.

    PerkinElmer points out that ViaCell offers expertise in the collection, testing, processing, and preservation of umbilical cord blood stem cells. The firm says, however, that it expects to divest ViaCell's therapeutic businesses. ViaCord sales are expected to be in the mid-to-high $60 million range in 2007, according to PerkinElmer. 

    The transaction is expected to close in the fourth quarter of 2007. PerkinElmer anticipates that related to its non-GAAP adjusted earnings per share it will be slightly dilutive in 2008 and accretive in 2009.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »